Novo Nordisk A/S (NVO) News
NYSE: NVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
38.64+0.46 (+1.20%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NVO news summary
We found 32 recent headlines mentioning Novo Nordisk A/S (NVO): 15 in the past week and 31 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, NVO is up 1.20% at $38.64. The most recent story, "UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Novo Nordisk A/S headlines
- UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.Key PointsUBS analyst Michael Yee believes investors prefer Eli Lilly's growth story to Novo Nordisk's turnaround story.NasdaqNVO, LLY
- LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?LLY's recent dip reflects valuation and competition concerns, but strong GLP-1 demand, pipeline growth and diversification support its long-term outlook.NasdaqLLY, NVO, VKTX, GPCR
- Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to KnowNovo Nordisk (NVO) reached $38.26 at the closing of the latest trading day, reflecting a +1.95% change compared to its last close.Nasdaq
- Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond ZepboundKey PointsEli Lilly has attractive pipeline candidates within its core therapeutic area.NasdaqLLY, NVO, AMGN
- Pharma lobby group sues Trump administration over MFN pricingSeeking Alpha
- VKTX Advances Obesity Program With New Oral Maintenance StudyVK2735's oral maintenance study could expand Viking Therapeutics' obesity strategy by helping sustain weight loss with less frequent dosing.NasdaqVKTX, NVO, LLY
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.NasdaqNVO, LLY, ALT, MDGL
- Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?Key PointsNovo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weight-loss drug.NasdaqNVO, LLY
- AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowAgios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.NasdaqAGIO, NVO, ALDX, ACIU
- Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?Key PointsEli Lilly and shows rapid expansion with metabolic health treatments and high revenue growth.NasdaqLLY, NVO
- VKTX Down 16% in a Month: Time to Invest or Exit the Stock?Viking Therapeutics faces dilution and rising obesity competition, but VK2735's pipeline progress could offer catalysts and support a rebound.NasdaqVKTX, NVO, LLY
- Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.Nasdaq
- Pfizer vs. J&J: Comparing Growth, Patent Risks and ValuationJ&J's diversified portfolio, new drug launches and sales growth give it an edge despite Pfizer's cheaper valuation and higher yield.NasdaqJNJ, PFE, NVO, LLY
- Novo's Denecimig BLA Review Delayed by FDA Facility Remediation WorkNVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.NasdaqNVO, ALDX, ACIU, PGEN
- Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?Key PointsNovo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited.NasdaqPFE, NVO, LLY
- Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension(RTTNews) - Novo Nordisk A/S (NVO), a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) informed the company that its Biologics License Application (BLA) review of…Nasdaq
- Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for InvestorsKey PointsNovo has improved its pipeline through licensing deals.Nasdaq
- Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?Key PointsNovo Nordisk maintains high profitability through its specialization in chronic disease management and metabolic health.NasdaqNVO, PFE
- DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes CareDexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.NasdaqDXCM, ABT, NVO, MMED
- Agios' Growth Story Hinges on Mitapivat's Commercial ExpansionAGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.NasdaqAGIO, NVS, BMY, NVO
- Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to WinLLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.NasdaqREGN, PFE, NVO, LLY
- Novo Nordisk: The Street Sold It For The Wrong ReasonSeeking Alpha
- 4 Stocks That Could Split Next—and Why Investors Are WatchingStock splits don't change fundamentals or company value; they do a lot for investors, ultimately driving equity gains. At face value, a stock split signals underlying company strength: the stock is…NasdaqAZO, ORLY, LLY, NVO
- Novo Nordisk: After A 70+% Drop, It's A Great InvestmentSeeking Alpha
- Novo Nordisk: Capital Markets Day Reveals Its Next Growth EngineSeeking Alpha
- Novo Nordisk: A Cheap Multiple Can't Fix Poor GrowthSeeking Alpha
- Novo Nordisk A/S (NOVO:CA) Analyst/Investor Day TranscriptSeeking Alpha
- Novo Nordisk A/S (NOVO:CA) Analyst/Investor Day - SlideshowSeeking Alpha
- Novo Nordisk A/S (NOVO:CA) Analyst/Investor Day - SlideshowSeeking Alpha
- Eli Lilly Vs. Novo Nordisk: Temporarily Cheap Or Correctly Cheap?Seeking Alpha
- Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.NasdaqCRBP, SNY, NVO, LLY
- After Hours Most Active for Aug 19, 2026 : WBS, NIO, LBRDK, NVDA, INTC, WMT, SUI, AAPL, NEE, NVO, VTR, SHYThe NASDAQ 100 After Hours Indicator is up 21.13 to 29,447.15. The total After hours volume is currently 170,366,966 shares traded.The following are the most active stocks for the after hours…NasdaqNVDA, INTC, WMT, SUI